Kiersten V. Summers

Array ( [id] => 16397270 [patent_doc_number] => 20200338128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => PRECISION MOLECULAR ADAPTOR SYSTEM FOR CAR-T IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/958915 [patent_app_country] => US [patent_app_date] => 2019-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506222 [patent_doc_number] => 20200385478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/959619 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14501389 [patent_doc_number] => 20190194349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => ANTIBODIES SELECTIVE FOR CELLS PRESENTING ERBB2 AT HIGH DENSITY [patent_app_type] => utility [patent_app_number] => 16/237363 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10501 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16237363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16261280 [patent_doc_number] => 10752700 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Methods and compositions relating to anti-CHI3L1 antibody reagents to treat nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NFALD) or metabolic syndrome [patent_app_type] => utility [patent_app_number] => 16/229128 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 21 [patent_no_of_words] => 33420 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16229128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581389 [patent_doc_number] => 20190218303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => CD37-Binding Molecules and Immunoconjugates Thereof [patent_app_type] => utility [patent_app_number] => 16/221747 [patent_app_country] => US [patent_app_date] => 2018-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16221747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18233217 [patent_doc_number] => 11597766 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Treatment of acute lymphoblastic leukemia [patent_app_type] => utility [patent_app_number] => 16/218797 [patent_app_country] => US [patent_app_date] => 2018-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12755 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 279 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16218797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14566945 [patent_doc_number] => 20190211079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => ENGINEERED HETERODIMERIC PROTEIN DOMAINS [patent_app_type] => utility [patent_app_number] => 16/217613 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16217613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072413 [patent_doc_number] => 20190085094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => IMMUNOGLOBULIN VARIANTS WITH ALTERED BINDING TO PROTEIN A [patent_app_type] => utility [patent_app_number] => 16/193327 [patent_app_country] => US [patent_app_date] => 2018-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16193327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929071 [patent_doc_number] => 20190048051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => POLYPEPTIDES TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND ALPHA V BETA 3 INTEGRIN [patent_app_type] => utility [patent_app_number] => 16/170310 [patent_app_country] => US [patent_app_date] => 2018-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16170310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277291 [patent_doc_number] => 20190135930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => B CELL MATURATION ANTIGEN BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 16/159545 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30520 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16159545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13901869 [patent_doc_number] => 20190040139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => METHODS OF ASSESSING AND TREATING CANCER IN SUBJECTS HAVING DYSREGULATED LYMPHATIC SYSTEMS [patent_app_type] => utility [patent_app_number] => 16/155726 [patent_app_country] => US [patent_app_date] => 2018-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16155726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452612 [patent_doc_number] => 20200362038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS [patent_app_type] => utility [patent_app_number] => 16/645785 [patent_app_country] => US [patent_app_date] => 2018-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14145505 [patent_doc_number] => 10253111 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => Methods and compositions relating to anti-Chi3l1 antibody reagents [patent_app_type] => utility [patent_app_number] => 16/124558 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 21 [patent_no_of_words] => 33408 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16124558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16290132 [patent_doc_number] => 10766968 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer [patent_app_type] => utility [patent_app_number] => 16/124575 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 15 [patent_no_of_words] => 40842 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16124575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14102369 [patent_doc_number] => 20190092860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => Covalent Diabodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/122437 [patent_app_country] => US [patent_app_date] => 2018-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16122437 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14102367 [patent_doc_number] => 20190092859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => Covalent Diabodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/120841 [patent_app_country] => US [patent_app_date] => 2018-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16120841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14102393 [patent_doc_number] => 20190092872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => ANTIBODY FC AND FAB VARIANTS [patent_app_type] => utility [patent_app_number] => 16/107454 [patent_app_country] => US [patent_app_date] => 2018-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44550 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16107454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467883 [patent_doc_number] => 20190185584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => PRODUCTION OF HETEROMULTIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 16/045539 [patent_app_country] => US [patent_app_date] => 2018-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16045539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16786119 [patent_doc_number] => 10988532 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-27 [patent_title] => Anti P2X [patent_app_type] => utility [patent_app_number] => 16/032973 [patent_app_country] => US [patent_app_date] => 2018-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 20159 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16032973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793387 [patent_doc_number] => 20190010232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => Checkpoint Inhibitor Bispecific Antibodies [patent_app_type] => utility [patent_app_number] => 16/029979 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9750 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 332 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029979 [rel_patent_id] =>[rel_patent_doc_number] =>)